Tarsus Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio11.5738.4215.158.16
P/B Ratio9.433.402.032.795.06
Price/Tangible Book9.793.472.032.795.06
Price/FCF147.13
Price/OCF124.13
Enterprise Value Ratios
EV/Revenue10.2426.097.154.96
EV/FCF89.41
Profitability & Returns
Return on Equity (ROE)-0.55%-0.70%-0.35%-0.08%-0.24%
Return on Assets (ROA)-0.23%-0.36%-0.19%-0.04%-0.15%
Return on Capital Employed (ROCE)-0.41%-0.63%-0.29%-0.07%-0.16%
Leverage & Solvency Ratios
Debt/Equity0.320.150.100.010.01
Debt/FCF0.38
Liquidity Ratios
Current Ratio4.426.9314.6115.3331.68
Quick Ratio4.216.6414.3014.9831.21
Efficiency Ratios
Asset Turnover0.570.070.130.33
Inventory Turnover23.12
Yield & Distribution Ratios
Earnings Yield-0.05%-0.20%-0.16%-0.03%-0.03%
FCF Yield-0.04%-0.18%-0.13%0.01%-0.03%
Buyback Yield-0.28%-0.19%-0.20%-2.31%-1.63%